FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kristian Bjøro

Research Profile

Procedures

Chemicals & Drugs

Disorders

Living Beings

Hepacivirus

Concepts & Ideas

Geographic Areas

Physiology

Genotype

Co-author Network

Publications

TOP 3
Arne Nørgaard Eskesen; Espen Melum; Amir Moghaddam; Helmer Ring-Larsen; Hans Verbaan; Kristian Bjøro; Olav Dalgard
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
Amir Moghaddam; Espen Melum; Nils Reinton; Helmer Ring-Larsen; Hans Verbaan; Kristian Bjøro; Olav Dalgard
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Tuva B Dahl; John Willy Haukeland; Arne Yndestad; Trine Ranheim; Ivar Gladhaug; Jan Kristian Damås; Terese Haaland; Else Marit Løberg; Borghild Arntsen; Kåre I Birkeland; Kristian Bjøro; Stine M Ulven; Zbigniew Konopski; Hilde I Nebb; Pål Aukrust; Bente Halvorsen
Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kristian Bjøro (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Arne Nørgaard Eskesen; Espen Melum; Amir Moghaddam; Helmer Ring-Larsen; Hans Verbaan; Kristian Bjøro; Olav Dalgard
Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
European journal of gastroenterology & hepatology 2012;24(8):890-6.
2011: Amir Moghaddam; Espen Melum; Nils Reinton; Helmer Ring-Larsen; Hans Verbaan; Kristian Bjøro; Olav Dalgard
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
Hepatology (Baltimore, Md.) 2011;53(3):746-54.
2010: Tuva B Dahl; John Willy Haukeland; Arne Yndestad; Trine Ranheim; Ivar Gladhaug; Jan Kristian Damås; Terese Haaland; Else Marit Løberg; Borghild Arntsen; Kåre I Birkeland; Kristian Bjøro; Stine M Ulven; Zbigniew Konopski; Hilde I Nebb; Pål Aukrust; Bente Halvorsen
Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease.
The Journal of clinical endocrinology and metabolism 2010;95(6):3039-47.
2009: Arne Yndestad; John Willy Haukeland; Tuva Børresdatter Dahl; Kristian Bjøro; Ivar Prydz Gladhaug; Christ Berge; Jan Kristian Damås; Terese Haaland; Else Marit Løberg; Paul Linnestad; Kåre I Birkeland; Zbigniew Konopski; Bente Halvorsen; Rolf Kristian Berge; Pål Aukrust
A complex role of activin A in non-alcoholic fatty liver disease.
The American journal of gastroenterology 2009;104(9):2196-205.
2009: John Willy Haukeland; Zbigniew Konopski; Heidi Beate Eggesbø; Hilde Løland von Volkmann; Gabriele Raschpichler; Kristian Bjøro; Terese Haaland; Else Marit Løberg; Kåre I Birkeland
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
Scandinavian journal of gastroenterology 2009;44(7):853-60.
2008: Olav Dalgard; Kristian Bjøro; Helmer Ring-Larsen; Einar Bjornsson; Mona Holberg-Petersen; Eva Skovlund; Olle Reichard; Bjørn Myrvang; Bo Sundelöf; Ståle Ritland; Kjell Block Hellum; Aril Frydén; Jon Florholmen; Hans Verbaan
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.
Hepatology (Baltimore, Md.) 2008;47(1):35-42.
2007: John Willy Haukeland; Inger Lorgen; Linn Therese Schreiner; Svein-Oskar Frigstad; Bjørn Brandsaeter; Kristian Bjøro; Christina Bang; Nils Raknerud; Zbigniew Konopski
Incidence rates and causes of cirrhosis in a Norwegian population.
Scandinavian journal of gastroenterology 2007;42(12):1501-8.
2007: Espen Melum; Styrbjörn Friman; Kristian Bjøro; Allan Rasmussen; Helena Isoniemi; Henrik Gjertsen; Lars Bäckman; Antti Oksanen; Michael Olausson; Frans Duraj; Bo-Göran Ericzon
Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma.
Journal of hepatology 2007;47(6):777-83.
2007: John Willy Haukeland; Kristian Bjøro
[When the brain fails in liver failure].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2007;127(11):1490.
2006: A Andriulli; Olav Dalgard; Kristian Bjøro; alessandra mangia
Short-term treatment duration for HCV-2 and HCV-3 infected patients.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2006;38(10):741-8.
2006: John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg L Goverud; Peter A Torjesen; Kåre I Birkeland; Kristian Bjøro; Pål Aukrust
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.
Journal of hepatology 2006;44(6):1167-74.
2006: Espen Melum; Erik Schrumpf; Kristian Bjøro
Liver TX for hepatitis C cirrhosis in a low prevalence population: risk factors and status at evaluation.
Scandinavian journal of gastroenterology 2006;41(5):592-6.
2006: Christine Slinning; Kristian Bjøro; Kirsten Muri Boberg; Erik Schrumpf
[Fulminant hepatic failure in malignant liver disease].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2006;126(7):917-8.
2006: Kristian Bjøro; Bjørn Brandsaeter; Aksel Foss; Erik Schrumpf
Liver transplantation in primary sclerosing cholangitis.
Seminars in liver disease 2006;26(1):69-79.
2005: John Willy Haukeland; Zbigniew Konopski; Paul Linnestad; Shafiullah Azimy; Else Marit Løberg; Terese Haaland; Kåre I Birkeland; Kristian Bjøro
Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease.
Scandinavian journal of gastroenterology 2005;40(12):1469-77.
2004: Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Ståle Ritland; Kjell Skaug; Nils Raknerud; Helge Bell
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.
Hepatology (Baltimore, Md.) 2004;40(6):1260-5.
2004: Bjørn Brandsaeter; Erik Schrumpf; Ole Petter F Clausen; Andreas Abildgaard; Geir Hafsahl; Kristian Bjøro
Recurrent sclerosing cholangitis or ischemic bile duct lesions--a diagnostic challenge?
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2004;10(8):1073-4.
2004: Bjørn Brandsaeter; Helena Isoniemi; Ulrika Broomé; Michael Olausson; Lars Bäckman; Bent Hansen; Erik Schrumpf; Antti Oksanen; Bo-Göran Ericzon; Krister Höckerstedt; Heikki Mäkisalo; Preben Kirkegaard; Styrbjörn Friman; Kristian Bjøro
Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy.
Journal of hepatology 2004;40(5):815-22.
2004: Kristian Bjøro; Erik Schrumpf
Liver transplantation for primary sclerosing cholangitis.
Journal of hepatology 2004;40(4):570-7.
2003: Bjørn Brandsaeter; Styrbjörn Friman; Ulrika Broomé; Helena Isoniemi; Michael Olausson; Lars Bäckman; Bent Hansen; Erik Schrumpf; Antti Oksanen; Bo-Göran Ericzon; Krister Höckerstedt; Heikki Mäkisalo; Preben Kirkegaard; Kristian Bjøro
Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries.
Scandinavian journal of gastroenterology 2003;38(11):1176-83.
2003: Bjørn Brandsaeter; Ulrika Broomé; Helena Isoniemi; Styrbjörn Friman; Bent Hansen; Erik Schrumpf; Antti Oksanen; Bo-Göran Ericzon; Krister Höckerstedt; Heikki Mäkisalo; Rolf Olsson; Michael Olausson; Preben Kirkegaard; Kristian Bjøro
Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2003;9(9):961-9.
2003: Eva M Moen; Solbjørg Sagedal; Kristian Bjøro; Miklos Degré; Per Kristian Opstad; Bjørn Grinde
Effect of immune modulation on TT virus (TTV) and TTV-like-mini-virus (TLMV) viremia.
Journal of medical virology 2003;70(1):177-82.
2003: Kristian Bjøro; Bjørn Brandsaeter; Kristine Wiencke; Trine Bjøro; Kristin Godang; Jens Bollerslev; Erik Schrumpf
Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
Scandinavian journal of gastroenterology 2003;38(3):320-7.
2003: Kristian Bjøro; Bo-Göran Ericzon; Preben Kirkegaard; Krister Höckerstedt; Gunnar Söderdahl; Michael Olausson; Aksel Foss; Lars E Schmidt; Helena Isoniemi; Bjørn Brandsaeter; Styrbjörn Friman
Highly urgent liver transplantation: possible impact of donor-recipient ABO matching on the outcome after transplantation.
Transplantation 2003;75(3):347-53.
2003: Arne Drivenes; Kristian Bjøro; Ellen Holter; Øystein Bentdal; Kirsten Muri Boberg
[Fulminant liver failure in acute hepatitis B virus infection].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2003;123(2):172-4.
2002: Bjørn Brandsaeter; Krister Höckerstedt; Styrbjörn Friman; Bo-Göran Ericzon; Preben Kirkegaard; Helena Isoniemi; Michael Olausson; Ulrika Broome; Lars Schmidt; Aksel Foss; Kristian Bjøro
Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2002;8(11):1055-62.
2002: S Distante; Kristian Bjøro; Kjell Block Hellum; B Myrvang; Jens Berg; Kjell Skaug; Nils Raknerud; Helge Bell
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.
Liver 2002;22(3):269-75.
2002: O Dalgard; Kristian Bjøro; Kjell Block Hellum; B Myrvang; Trine Bjøro; E Haug; H Bell
Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy.
Journal of internal medicine 2002;251(5):400-6.
2002: Helge Bell; Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang
[Treatment of chronic hepatitis C].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 2002;122(9):926-8.
2002: Kristian Bjøro; Helge Bell; Bjørn Myrvang; Kjell Skaug; Nils Raknerud; P Sandvei; S Størseth; Ståle Ritland; S Lund-Tønnesen; A Bucher; Kjell Block Hellum
Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
Scandinavian journal of gastroenterology 2002;37(3):344-9.
2002: Kristian Bjøro; Helge Bell; Kjell Block Hellum; Kjell Skaug; Nils Raknerud; P Sandvei; B Døskeland; A Maeland; S Lund-Tønnesen; Bjørn Myrvang
Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
Scandinavian journal of gastroenterology 2002;37(2):226-32.
2002: Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Kjell Skaug; BG Gutigard; Helge Bell
Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.
European addiction research 2002;8(1):45-9.
2001: Kristian Bjøro; Preben Kirkegaard; Bo-Göran Ericzon; Styrbjörn Friman; Erik Schrumpf; Helena Isoniemi; Gustaf Herlenius; Michael Olausson; A Rasmussen; Aksel Foss; K Höckerstedt
Is a 3-day limit for highly urgent liver transplantation for fulminant hepatic failure appropriate, and is the diagnosis in some cases incorrect?
Transplantation proceedings 2001;33(4):2511-3.
2000: Kristian Bjøro; Krister Höckerstedt; Bo-Göran Ericzon; Styrbjörn Friman; A Hjortrup; S Keiding; Erik Schrumpf; Frans Duraj; Michael Olausson; Heikki Mäkisalo; Anstein Bergan; Preben Kirkegaard
Liver transplantation in patients over 60 years of age.
Transplant international : official journal of the European Society for Organ Transplantation 2000;13 Suppl 1():S165-70.
1999: O Søreide; B Husberg; Kristian Bjøro; Erik Schrumpf
[Liver transplantation--development and experiences].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1999;119(22):3310-4.
1999: Kristian Bjøro; Kjell Skaug; Terese Haaland; SS Frøland
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.
QJM : monthly journal of the Association of Physicians 1999;92(8):433-41.
1999: Kristian Bjøro; Styrbjörn Friman; Krister Höckerstedt; Preben Kirkegaard; S Keiding; Erik Schrumpf; Michael Olausson; Antti Oksanen; Helena Isoniemi; A Hjortrup; Anstein Bergan; Bo-Göran Ericzon
Liver transplantation in the Nordic countries, 1982-1998: changes of indications and improving results.
Scandinavian journal of gastroenterology 1999;34(7):714-22.
1999: Kristian Bjøro; Terese Haaland; Kjell Skaug; SS Frøland
The spectrum of hepatobiliary disease in primary hypogammaglobulinaemia.
Journal of internal medicine 1999;245(5):517-24.
1999: Helge Bell; Kjell Block Hellum; S Harthug; Bjørn Myrvang; Ståle Ritland; A Maeland; Bent von der Lippe; Kristian Bjøro; Kjell Skaug; BG Gutigard; Nils Raknerud; Peter Simmonds
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Scandinavian journal of gastroenterology 1999;34(2):194-8.
1998: Kristian Bjøro; L Gjerstad; Oystein Bentdal; S Osnes; E Schrumpf
Topiramate and fulminant liver failure.
Lancet 1998;352(9134):1119.
1998: Kristian Bjøro; Erik Schrumpf; Anstein Bergan; Terese Haaland; Kjell Skaug; SS Frøland
Liver transplantation for endstage hepatitis C cirrhosis in a patient with primary hypogammaglobulinaemia.
Scandinavian journal of infectious diseases 1998;30(5):520-2.
1997: S Keiding; K Høckerstedt; Kristian Bjøro; Stig Bondesen; A Hjortrup; Helena Isoniemi; C Erichsen; Gunnar Söderdahl; Bo-Göran Ericzon
The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients.
Transplantation 1997;63(11):1591-4.
1997: Kristian Bjøro; J P Blomhoff; Erik Schrumpf; Frank Brosstad; Anstein Bergan; T Egge
[Hepatic vein thrombosis. Diagnostic and therapeutic difficulties].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1997;117(9):1274-6.
1996: Kristian Bjøro; Erik Schrumpf; Anstein Bergan; A Flatmark; Oystein Mathisen; G Sødal; Odd Søreide; T Sanengen; R Innes; S Osnes
[Liver transplantation in Norway. Results after 10 years and 114 transplantations].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1996;116(1):19-24.
1994: Kristian Bjøro; Stig S Frøland; Z Yun; H H Samdal; Terese Haaland
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin.
The New England journal of medicine 1994;331(24):1607-11.
1992: Kristian Bjøro; Erik Schrumpf
[Hepatitis C].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1992;112(29):3654-5.
1990: Kristian Bjøro; M Vatn; Erik Schrumpf; T Ganes; T Lundar; Anstein Bergan
[Liver transplantation in fulminant hepatic failure].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1990;110(26):3372-5.
1990: Kristian Bjøro; Erik Schrumpf; K Elgjo; K Nordgård
[Chronic non-A non-B hepatitis treated with interferon].
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række 1990;110(11):1346-8.